Ureter benign neoplasm
Therapeutic area
Nephrology
Rare disease
No
- Definition
- Cancer or tumors of the ureter which may cause obstruction leading to hydroureter, hydronephrosis, and pyelonephritis. hematuria is a common symptom.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Ureter benign neoplasm
- Therapeutic area
- Nephrology
- ureter benign neoplasm
- ureteral tumor
- ureteral tumour
- benign neoplasm of the ureter
- benign neoplasm of ureter
- benign tumor of the ureter
- benign tumor of ureter
- benign tumour of the ureter
- benign tumour of ureter
- benign ureter neoplasm
- benign ureter tumor
- benign ureter tumour
- benign ureteral neoplasm
- benign ureteral tumor
- benign ureteral tumour
- benign ureteric neoplasm
- ureter benign neoplasm
- Severity
- Severe
- Nephrology
- Oncology
- MONDO ID
- MONDO:0001398
- Parent condition
- MONDO:0004180
Related records
Broader conditions (13)
- Benign neoplasm
- Benign urinary system neoplasm
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Ureter neoplasm
- Ureteral disorder
- Urinary system disorder
- Urinary system neoplasm
Narrower conditions (4)
- Schwannoma of ureter
- Ureter inverted papilloma
- Ureter leiomyoma
- Ureter urothelial papilloma
Trials (79)
- A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
- A Genotype-Phenotype Urothelial Cancer Registry
- A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
- A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
- Afatinib in Advanced Refractory Urothelial Cancer
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- ARID1A and/or KDM6A Mutation and CXCL13 Expression
- Arsenic Trioxide in Treating Patients With Urothelial Cancer
- Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
- Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer